Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Cr, down 22.6% YoY due to delivery timing shifts.

Anthem Biosciences LimitedANTHEM · Filed with the exchange

EBITDA was ₹175.5 Cr (39.6% margin) and PAT ₹119.9 Cr (27.1% margin). Management expects strong H2FY27 deliveries and sustained industry-leading margins.

Read the original filing(PDF)

No comments yet. Be the first.

More from Anthem Biosciences Limited

All announcements

Updates08-09-2026
Updates
Investor Meet27-07-2026
Analysts/Institutional Investor Meet/Con. Call Updates
Others24-07-2026
Shareholders meeting
Others22-07-2026
Copy of Newspaper Publication
PPTs21-07-2026
Investor Presentation
Updates21-07-2026
Press Release

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.